Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064034 · ClinicalTrials.gov registry record · NA
ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT04064034: Completed NA study, sponsored by Mayo Clinic.
NCT04064034 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04064034, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.
Interventions
- OTHER Lateral Flow Assay (LFA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2020-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04064034
The ClinicalTrials.gov registry entry for NCT04064034 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lateral Flow Assay (LFA) is the first listed.
NCT04064034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04064034 about?
NCT04064034 is a clinical study titled "ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer". Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancre...
What is the current status of trial NCT04064034?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2019-08-01. Estimated completion is 2020-10-31.
What interventions are being tested in trial NCT04064034?
The interventions under investigation include: Lateral Flow Assay (LFA) (OTHER).
Who is sponsoring clinical trial NCT04064034?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.